Remove Branding Remove Development Remove Generic Pharmaceutical Remove Life Science
article thumbnail

Novartis’ Sandoz Launches Biosimilars Awareness Campaign to Improve Biosimilars Adoption Worldwide

XTalks

Sandoz is a pioneering leader in generic pharmaceuticals and biosimilars, as Sandoz launched the world’s first biosimilar in Europe in 2006 and won the first biosimilar approval in the US in 2014. Among them are “ensuring equitable pricing, involving patients in treatment decisions and streamlining biosimilar development.”.

article thumbnail

New Sandoz Board of Directors appointed

The Pharma Data

The Sandoz Board of Directors will have 10 members in total and 3 sub-committees: a Science, Innovation & Development Committee, a Human Capital & ESG Committee and an Audit, Risk & Compliance Committee. She is also a board member at BBI Solutions, a UK based diagnostic reagents and a Novo Holdings company. Dr. Shamiram R.

Sales 40